Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

This summary is generated by an algorithm. If you find any mistakes, let us know.

Elligo Health Research Inks $135M Series E
Elligo Health Research Inks $135M Series E
UN

Unicorn Nest news

Elligo Health Research Inks $135M Series E

– Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo technology, announced a $135m Series E financing round.
Morgan Stanley Expansion Capital and Ally Bridge Group participated in the financing round.
– The round was also participated by Norwest Venture Partners and all major existing investors, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler Merchant Banking, Shumway Capital, and Syneos Health.
– This financing allows Elligo to invest further in its technology platform and leverage data in new ways to address current challenges in the clinical trial industry.

Source
Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care
Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care
UN

Unicorn Nest news

Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care

– Imperative Care, Inc. announced that it has closed a $260m Series D financing led by D1 Capital Partners.
– New investors HealthCor Investments LLC and Innovatus Capital Partners also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the financing.
– James Rogers from D1 will join Imperative Care’s Board of Directors.
– Proceeds from the financing will be used to support ongoing commercialization and development of a wide range of Imperative Care’s technologies in the broad continuum of stroke care, as well as to create a strategic network of wholly owned development subsidiaries in a number of areas of synergy.

Source
CMR Surgical Raises $600M in Series D Funding
CMR Surgical Raises $600M in Series D Funding
UN

Unicorn Nest news

CMR Surgical Raises $600M in Series D Funding

– CMR Surgical is a Cambridge UK-based surgical robotic company.
– Series D $600M round was led by SoftBank Vision Fund 2 with participation from Ally Bridge Group, new investors RPMI Railpen, Tencent and Chimera, and existing investors LGT and its affiliate impact investing platform Lightrock, Watrium, Cambridge Innovation Capital, PFM Health Sciences and GE Healthcare.
– The investment will be used for the global commercialization of Versius and further develop the company’s digital ecosystem.

Source
Strateos Closes $56 Million Series B Financing to Accelerate the Roll-Out of its SmartLab of the Future Platform
Strateos Closes $56 Million Series B Financing to Accelerate the Roll-Out of its SmartLab of the Future Platform
UN

Unicorn Nest news

Strateos Closes $56 Million Series B Financing to Accelerate the Roll-Out of its SmartLab of the Future Platform

– Strateos, Inc. announced the closing of its $56.1m Series B financing led by DCVC and Lux Capital with participation from new investors including Eli Lilly and Company, Ally Bridge Group, Black Diamond Ventures, Mack & Co., LLC, and Castor Ventures.
– With this financing, Strateos will continue to drive innovations on its SmartLab Platform™, which integrates data generation and AI-enablement with its unique and flexible automation to accelerate pharmaceutical and synthetic biology R&D.
– Life science research needs faster, more reliable and lower cost data to fully leverage AI-powered analysis tools.
– Strateos is pleased to have the backing of these world-class investors who bring deep expertise in building and scaling innovative platforms at the intersection of the life sciences and information technology.

Source
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
UN

Unicorn Nest news

NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

– NiKang Therapeutics Inc. announced the completion of an oversubscribed $200m series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors with participations from a premier syndicate of funds including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital.
– All existing investors including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital participated in the financing.

Source
Hummingbird Bioscience Raises US$125M in Series C Financing
Hummingbird Bioscience Raises US$125M in Series C Financing
UN

Unicorn Nest news

Hummingbird Bioscience Raises US$125M in Series C Financing

– Hummingbird Bioscience from Singapore develops precision therapies against hard-to-drug targets to improve treatment outcomes.
– Series C $125m round brings company valuation to more than $1b.
– The round was led by Novo Holdings with participation from new investors – Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital.

Source
Ultivue Announces $50M Financing Round
Ultivue Announces $50M Financing Round
UN

Unicorn Nest news

Ultivue Announces $50M Financing Round

– Ultivue announced the completion of a $50m Series D round of financing.
– New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners.
– Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.
– This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.

Source
RefleXion Adds Ally Bridge Group to Investor Syndicate
RefleXion Adds Ally Bridge Group to Investor Syndicate
UN

Unicorn Nest news

RefleXion Adds Ally Bridge Group to Investor Syndicate

– RefleXion Medical announced the successful completion of a $40m Series D financing round bringing total investment in the company to $150m.
– The round was led by Ally Bridge Group (ABG) and includes participation from the company’s executive leadership, NewView Capital, and Georgian Partners.
– RefleXion is pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer.
– RefleXion X1 machine with BgRT is designed to overcome the technical limitations that currently restrict radiotherapy to one or two tumors.
– When available, RefleXion will scale BgRT to treat all visible tumors, even those that move rapidly due to bodily functions such as breathing or digestion, in the same treatment session.

Source
Mainstay Medical Receives US$108M Equity Financing
Mainstay Medical Receives US$108M Equity Financing
UN

Unicorn Nest news

Mainstay Medical Receives US$108M Equity Financing

– Mainstay Medical Holdings, a Dublin, Ireland-based medical device company focused on commercializing an innovative implantable restorative neurostimulation system for people with disabling mechanical Chronic Low Back Pain, closed an equity financing of US$108m.
– The round was co-led by new investors Ally Bridge Group and Sofinnova Partners, through its Crossover Fund, and also included a large, global medical device company.
– Key existing investors participating include Sofinnova Partners (Capital Fund), KCK Group and Fountain Healthcare Partners.

Source
1 2 3 58 59 60
Crunchbase icon

Content report

The following text will be sent to our editors: